Latest
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
Read Article![](https://beringcapital.com/wp-content/uploads/2023/01/shutterstock_1697025442-scaled-aspect-ratio-209-135-1-scaled.jpg)
Scientific Inquirer: Industry Matters: From Elite Responders to M2 macrophages – OncoResponse’s approach to cancer immunotherapy
Read Article![](https://beringcapital.com/wp-content/uploads/2023/06/home-image-3-aspect-ratio-209-135.jpg)
Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-guideline Genomic Factors
Read Article![](https://beringcapital.com/wp-content/uploads/2022/10/Lung-cancer-KRAS-nci-vol-10549-300-scaled-aspect-ratio-209-135-scaled.jpg)
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis®
Read Article![](https://beringcapital.com/wp-content/uploads/2022/08/shutterstock_1946757691-scaled-aspect-ratio-209-135-scaled.jpg)
Cellworks: Predictions of Overall Survival And Progression-Free Survival For Therapeutic Interventions In Glioblastoma Multiforme
Read Article![](https://beringcapital.com/wp-content/uploads/2022/07/national-cancer-institute-to8o0bqOA6Q-unsplash-scaled-aspect-ratio-209-135-scaled.jpg)
Cellworks Singula Therapy Response Index (TRI) Predicts Clinical Outcomes For Esophageal Adenocarcinoma: MyCare-004
Read Article![](https://beringcapital.com/wp-content/uploads/2022/07/shutterstock_617485316-scaled-aspect-ratio-209-135-scaled.jpg)
Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer
Read Article![](https://beringcapital.com/wp-content/uploads/2022/07/shutterstock_536024212-aspect-ratio-209-135.jpg)